

Luis Rojas-Espailat, MD

Avera Medical Group Gynecologic Oncology
 Avera Cancer Institute
 1000 East 23rd Street
 Sioux Falls, SD 57105
Luis.RojasEspailat@avera.org
 Phone: 605-322-7535

Medical Journey

Professional experience

Present Clinical Positions	2007 – Present	Physician/Active clinical staff Avera Medical Group Gynecologic Oncology Avera Cancer Institute, Sioux Falls, SD
	2011 – Present	Clinical Associate Professor Department of obstetrics and gynecology Sanford school of medicine University of South Dakota, Vermillion, SD
Current Clinical Staff Appointments	2007 – Present	Avera McKennan Hospital and University Health Center Sioux Falls, SD
	2007 – Present	Consulting staff in the medicine department Avera Heart Hospital of South Dakota, Sioux Falls, SD
	2013 – Present	Consulting Medical Staff Avera Queen of Peace Hospital, Mitchell, SD

Education

Residency and Internship	Jun 2000 - June 2004	Resident in Obstetrics and Gynecology Temple University Hospital Philadelphia, PA.
	Jun 2004 - June 2007	Fellow in Gynecologic Oncology The Cleveland Clinic Cleveland, OH
Medical Education	April 1998	Doctor in Medicine (Magna Cum Laude) Universidad Nacional Pedro Henrriquez Urena (UNPHU) Santo Domingo, Dominican Republic
Pre-Medical Education	Aug 1993	Bachelor in Premedical Science Universidad Nacional Pedro Henrriquez Urena (UNPHU) Santo Domingo, Dominican Republic

Board Certifications	12/11/2009	Obstetrics and Gynecology (ABOG 9008506)
	4/18/2012	Gynecologic Oncology (ABOG 9008506)

Leadership Journey

Current Leadership Role	2023 - 2024	Clinical Vice President, One Avera Oncology Service Line. Avera Health, Sioux Falls, South Dakota
Leadership Experience	2016 - 2023	Clinical Vice President, Medical Oncology, Cancer Service Line. Avera Health, Sioux Falls, South Dakota.
	2018 - Present	Member Avera Health Board of Directors. Avera Health, Sioux Falls, South Dakota.
	2022 - 2024	Chair, Avera Health Board of Directors Avera Health, Sioux Falls, South Dakota.
	2017 - Present	Medical Director and Chair, Avera Cancer Institute Cancer Leadership Committee Avera McKennan Hospital and University Health Center Sioux Falls, South Dakota.
	2016 – 2018.	Member Avera McKennan Hospital Board of Trustees. Avera McKennan Hospital and University Health Center Sioux Falls, South Dakota.
	2014 – 2016	Secretary / Treasurer of the medical staff. Avera McKennan Hospital and University Health Center Sioux Falls, South Dakota.
	2011 - 2015	Chair, Obstetrics and Gynecology Avera McKennan Hospital and University Health Care Center Sioux Falls, SD
	2012 - 2013	Clinical Preceptor Master of science in nursing program Clarkson college, Omaha, NE
	2009 – 2011	Vice-Chair, Obstetrics and Gynecology Avera McKennan Hospital and University Health Care Center Sioux Falls, SD
2008 – 2013	Chair, Robotic Surgery Subcommittee Avera McKennan Hospital and University Health Care Center Sioux Falls, SD	

**Leadership
Education**

September 2024 (ongoing)	Illuminate Avera Health Sioux Falls, SD
May 2021	Dyad Leadership Academy Avera Health Sioux Falls, SD.
2018	Finance 101 for physicians Avera Health Sioux Falls, SD
2016	Crucial Conversations Avera Health Sioux Falls, SD
2013 -2014	Physician Academy Class 2 Avera Health Sioux Falls, SD

Medical Licenses

2007 - present	South Dakota #6020
2014 - present	Minnesota Telemedicine #1952

**Professional
Memberships**

2015 – Present	American Society of Clinical Oncology (458736) Member
2005 – Present	Society of Gynecologic Oncologists: (No. 10241) Candidate member 2005 – 2012 Member, Clinical Practice Committee 2011 – 2012 Member, 2012 – present
2000 – Present	American Congress of Obstetrics and Gynecology Junior fellow, 2000 – 2010 (No, 0434390) Fellow, 2010 – Present
2007 – Present	South Dakota State Board of Medical Association: Member
1998 – Present	Dominican Medical Association: Member (No. 15268)

Research Interests

- Molecular profiling and genomic signatures of gynecologic malignancies.
- Obesity and metabolism effects in endometrial malignancies.
- Applications of minimally invasive technology in gynecologic cancers.
- Clinical trial designs.

Research Experience

Member of NRG and Investigator for NCI and Industry Studies

Clinical Trials

- 2022 GSK 213357:** Cohort C: Open-label Phase 2, Randomized, Controlled Multicenter Study Comparing Niraparib Versus Platinum-Taxane Doublet Chemotherapy as Neoadjuvant Treatment in Participants with Homologous Recombination-deficient Stage III/IV Ovarian Cancer (OPAL)
- 2022 ELU-Fra-1:** Dose Escalation and Expansion Clinical Study to Evaluate the Safety and Efficacy of ELU001 in Subjects who have advanced, recurrent or refractory FRa overexpressing tumors.
- 2020 D9311C00001-GOG-3041:** A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination with Durvalumab, Followed by Maintenance Durvalumab with or without Olaparib in Patients with Newly Diagnosed Advanced or Recurrent Endometrial Cancer (**DUO-E**)
- 2019 NRG-GY018:** A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
- 2019 NRG-GY019:** A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
- 2018 CO-338-087/ATHENA:** CO-338-087: ATHENA (A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Nivolumab and Rucaparib Combination Switch Maintenance Following Front-Line Platinum-Based Chemotherapy in Ovarian Cancer Patients)
- 2018 TESARO 3000-03-005/ENGOT-OV44:** The FIRST: A randomized, Double-Blind, Phase 3 comparison of platinum-based therapy with TSR 042 and niraparib versus standard of care platinum-based therapy as First line treatment of stage III or IV nonmucinous Epithelial ovarian cancer
- 2018 Takeda: X31025:** A Phase 1 Evaluation of the Safety and Tolerability of TAK-128 in Combination with TAK-117 and Paclitaxel in Advanced Solid Tumors
- 2018 Tesaro: TNE001:** A Phase 1 Evaluation of the Safety and Tolerability of Niraparib in Combination with Everolimus in Advanced Ovarian and Breast Cancer
- 2017 Regeneron R2810-ONC-1676/GOG-3016 (CVP1601):** An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Therapy of Investigator's Choice Chemotherapy in Recurrent or Metastatic Platinum-Refractory Cervical Carcinoma
- 2016 NRG-GY003:** Phase II Randomized Trial of Nivolumab with or without Ipilimumab in Patients with Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
- 2016 Astra Zeneca D8488C00001:** A single arm, open-label, Phase Iib study to assess the efficacy and safety of the combination of cediranib and olaparib tablets in women with recurrent platinum resistant epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer who do not carry a deleterious or suspected deleterious germline BRCA mutation

- 2016 Pfizer B9991010:** A Randomized, Open-Label, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Avelumab (MSB0010718C) in Combination with and/or Following Chemotherapy in Patients with Previously Untreated Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)
- 2016 PR-30-5017-C: GOG 3012** A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
- 2015 N1048: A Phase II/III trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision**
- 2015 NRG-GY001:** A Phase II Trial of Cabozantinib (XL-184) (NSC #761968) in Women with Recurrent, Clear Cell Carcinoma of the Ovary, Fallopian Tube, or Peritoneum
- 2015 NRG-CC002:** Pre-operative Assessment and Post-Operative Outcomes of Elderly Women with Gynecologic Cancers
- 2015 Investigator Initiated GSB-G2:** Molecular Genetic Profiling in Gynecological Sarcoma
- 2010 Investigator Initiated GSB-G1:** Gynecologic Specimen Bank for Genetic and Genomic Investigation
- 2015 Investigator Initiated:** A Retrospective Review of Advanced Gynecologic Malignancies Managed with the Aid of Comprehensive Genomic Profiling (CGP) and Proteomic Analysis (PA)
- 2014 GOG 0264:** A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemo-naïve Stage Sex Cord-Stromal Tumors of the Ovary
- 2014 GOG 0281:** A Randomized Phase II/III Study To Assess The Efficacy of Trametinib (GSK 1120212) In Patients With Recurrent Or Progressive Low-Grade Serous Ovarian Cancer Or Peritoneal Cancer.
- 2014 GOG 0286B:** A Randomized Phase II/III Study Of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo As Initial Therapy For Measurable Stage III Or IVA, Stage IVB, or Recurrent Endometrial Cancer
- 2014 RTOG-0724:** Phase III Randomized Study of Concurrent Chemotherapy and Pelvic RADIATION THERAPY With or Without Adjuvant Chemotherapy in High-Risk Patients with Early-stage Cervical Carcinoma Following Radical Hysterectomy
- 2014 GOG 0249:** A Phase III Trial of Pelvic Radiation Therapy versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin in Patients with High-Risk, Early Stage Endometrial Cancer
- 2014 GOG 0252:** A Phase III Clinical Trial Of Bevacizumab With IV Versus IP Chemotherapy In Ovarian, Fallopian Tube, And Primary Peritoneal Carcinoma Bevacizumab
- 2014 GOG 0209:** A Randomized Phase III Trial Of Doxorubicin/Cisplatin/Paclitaxel/G-CSF Versus Carboplatin/Paclitaxel In Patients With Stage III & IV Or Recurrent Endometrial Cancer Molecular Genetic Profiling in Gynecological Sarcoma
- 2014 RTOG-1203:** A Randomized Phase III Study of Standard vs. IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C)
- 2013 AstraZeneca D0818C00001 GOG 3004:** A Phase III, Randomized, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer Following First Line Platinum Based Chemotherapy.
- 2013 GOG 0244:** THE LYMPHEDEMA AND GYNECOLOGIC CANCER (LEG) STUDY: INCIDENCE, RISK FACTORS, AND IMPACT IN NEWLY DIAGNOSED PATIENTS

- 2012 GOG 3001 TRINOVA-3:** A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 With Paclitaxel and Carboplatin as First-line Treatment of Subjects With FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers
- 2011 GOG 0238:** A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus
- 2011 GOG 0263:** Randomized Phase III Clinical Trial Of Adjuvant Radiation Versus Chemoradiation In Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy And Pelvic Lymphadenectomy.
- 2010 GOG 0258:** A Randomized Phase III Trial Of Cisplatin And Tumor Volume Directed Irradiation Followed By Carboplatin And Paclitaxel Vs. Carboplatin And Paclitaxel For Optimally Debulked, Advanced Endometrial Carcinoma
- 2010** Chemotherapy- Naïve Patients With Newly Diagnosed Stage I-IV Persistent Or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) Of The Uterus
- 2008 GOG 0213:** A Phase III randomized controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab (NSC #704865, IND #7921) followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, fallopian tube and peritoneal primary cancer.
- GOG 0210:** A Molecular Staging Study of Endometrial Carcinoma
- GOG 0212:** A Randomized Phase III Trial of Maintenance Chemotherapy Comparing 12 Monthly Cycles of Single Agent Paclitaxel or Xyotax Versus no Treatment until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy

PUBLICATIONS

Rojas-Espailat, L.A.; Gonzalez, C.F.; Alburquerque, R.; Contreras, F.A: BARRETT's ESOPHAGUS: Behavior and risk factors of the disease, in middle-high socioeconomic status patients in the Dominican Republic. UNPHU 03/1998

Escobar, P.F; **Rojas-Espailat, L.A.;** Belinson, J.L.: Optical diagnosis of cervical Dysplasia. Int J Gynaecol Obstet. 2005 Apr;89(1):63-4

Rojas-Espailat, LA; Rose PG. Treatment of locally advanced cervical cancer. Curr Op Oncol; 2005 Sept;17(5):485-92.

Escobar PF, **Rojas-Espailat L,** Tisci S, Enerson C, Brainard J, Smith J, Tresser NJ, Feldchtein FI, Rojas LB, Belinson JL: Optical coherence tomography as a diagnostic aid to visual inspection and colposcopy for preinvasive and invasive cancer of the uterine cervix. Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1815-22.

Rojas-Espailat LA, Houck K, Hernandez E, Berkowitz R: Fertility Sparing Surgery for Persistent Gestational Trophoblastic Neoplasia in the Myometrium. J Reprod Med. 2007 May;52(5):431-4

Han X, Shen T, **Rojas-Espailat, LA,** Hernandez E. Giant cell fibroblastoma of the vulva at the site of a previous fibroepithelial stromal polyp. J Low Genit Tract Dis. 2007 apr 11(2): 112-7

Fader AN, **Rojas-Espailat L,** Ibeanu O, Grumbine FC, Escobar PF. Laparoendoscopic single-site surgery (LESS) in gynecology: a multi-institutional evaluation. Am J Obstet Gynecol. 2010 Jul 19.

Escobar PF, Starks DC, Fader AN, Barber M, **Rojas-Espalliat L.** Single-port risk-reducing salpingo-oophorectomy with and without hysterectomy: surgical outcomes and learning curve analysis. Gynecol Oncol. 2010 Oct;119(1):43-7.

Fader AN, Rasool N, Vaziri SA, Kozuki T, Faber PW, Elson P, Biscotti CV, Michener CM, Rose PG, **Rojas-Espailat L,** Belinson JL, Ganapathi MK, Ganapathi R. CCL2 expression in primary ovarian carcinoma is correlated with chemotherapy response and survival outcomes. Anticancer Res. 2010 Dec;30(12):4791-8.

AK Krie, K N Bohlen, Y Hu, C Ageton, H Emuth, D Norfolk, J Kittelsrud, R Thomes, A Fahendorf, J Muth, **LA Rojas-Espaillet**, GE Davies. Low carbohydrate dietary intervention improves insulin, hormonal levels and inflammatory markers in early stage, postmenopausal breast cancer survivors. *Cancer Res* December 15, 2013 73:PD2-5; doi:10.1158/0008-5472.SABCS13-PD2-5.

AK Krie, K N Bohlen, Y Hu, C Ageton, H Demuth, D Norfolk, J Kittelsrud, R Thomes, A Fahendorf, J Muth, **LA Rojas-Espaillet**, GE Davies. Improved quality of life for early stage breast cancer survivors on a low carbohydrate calorie restricted dietary intervention. *Cancer Res* December 15, 2013 73:P3-09-16; doi:10.1158/0008-5472.SABCS13-P3-09-16

AK Krie, K N Bohlen, Y Hu, C Ageton, H Demuth, D Norfolk, J Kittelsrud, R Thomes, A Fahendorf, J Muth, **LA Rojas-Espaillet**, GE Davies. Weight loss and lipid-lowering efficacy of a low carbohydrate, calorie restricted diet intervention on postmenopausal breast cancer patients. *Cancer Res* December 15, 2013 73:P4-09-04; doi:10.1158/0008-5472.SABCS13-P4-09-04

Luis Rojas, Casey B. Williams, Siraj Mahamed Ali, Kirstin Anne Williams, David Starks, Mark Bailey, Jie He, Julia Andrea Elvin, Norma Alonzo Palma, Nandini Dey, Pradip De, Philip J. Stephens, Vincent A. Miller, Jeffrey S. Ross, Brian Leyland-Jones; Avera Cancer Institute, Sioux Falls, SD; Foundation Medicine, Inc., Cambridge, MA; Albany Medical College, Albany, NY. Frequency of clinically relevant genomic alterations using comprehensive genomic profiling (CGP) for the management of advanced gynecologic malignancies in a community setting. *J Clin Oncol* 33, 2015 (suppl; abstr e22068).

Yihua Liu, Zachary Weber, F. Anthony San Lucas, Aditya Deshpande, Yasminka A. Jakubek, Raed Sulaiman, Mary Fagerness, Natasha Flier, Joseph Sulaiman, Christel M. Davis, Jerry Fowler, David Starks, **Luis Rojas-Espaillet**, Alexander J. Lazar, Gareth E. Davies, Erik A. Ehli, Paul Scheet. Assessing inter-component heterogeneity of biphasic uterine carcinosarcomas. *Gynecologic Oncology* 151 (2018) 243–249

De P, Aske JC, Dale A, **Rojas Espaillet L**, Starks D, Dey N. Addressing activation of WNT beta-catenin pathway in diverse landscape of endometrial carcinogenesis. *Am J Transl Res*. 2021 Nov 15;13(11):12168-12180. eCollection 2021. PMID: 34956444 Review

Starks DC, **Rojas-Espaillet L**, Meissner T, Williams CB. Phase I dose escalation study of dual PI3K/mTOR inhibition by Sapanisertib and Serabelisib in combination with paclitaxel in patients with advanced solid tumors. *Gynecol Oncol*. 2022 Sep;166(3):403-409. doi: 10.1016/j.ygyno.2022.07.005. Epub 2022 Jul 15. PMID: 35843739 Clinical Trial

Starks D, **Rojas-Espaillet L**, Meissner T, Elsey R, Xu B, Koenen M, Feng S, VanOosbree A, Slunecka J, Lee J, Williams CB. A phase 1 evaluation of the safety and tolerability of niraparib in combination with everolimus in advanced ovarian and breast cancers. *Cancer Med*. 2023 Aug 30. doi: 10.1002/cam4.6475. PMID: 37644890